Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Sorafenib and sunitinib, novel anti-tumor agents approved for the treatment of renal cell carcinoma, have been associated with multiple adverse cutaneous effects. To further investigate the constellation of possible adverse effects of sorafenib and sunitinib on the skin. Case report of a 62 year old male with history of renal cell carcinoma treated with adjuvant sorafenib. Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib. Further investigation regarding the possible adverse cutaneous effects of sorafenib and sunitinib, pathogenesis and risk factors for development, associated time course, and preventative and therapeutic methods, will allow for better patient and physician education.